Core Viewpoint - The AI-driven drug discovery and development company Insilico Medicine (3696.HK) experienced a significant intraday increase of 17%, reaching a new high of 55 HKD, marking a cumulative increase of over 52% since its listing, with a market capitalization exceeding 30 billion HKD [1] Company Summary - Insilico Medicine's stock price surged to a peak of 55 HKD, reflecting strong investor interest and confidence in its AI-driven drug development capabilities [1] - The company has achieved a remarkable cumulative gain of over 52% since its initial public offering, indicating robust market performance [1] - With a market capitalization surpassing 30 billion HKD, Insilico Medicine is positioned as a significant player in the biotechnology sector [1]
港股英矽智能盘中大涨17%，股价创上市新高，市值超300亿港元